시장보고서

상품코드

1591395

항생제 및 항진균제 시장 규모 및 예측, 세계 및 지역별 점유율, 동향, 성장 기회 분석 보고서 : 약물군별, 적응증별, 투여 경로별, 유통 채널별, 지역별

Antibiotics and Antimycotics Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Drug Class, Indication, Route of Administration, Distribution Channel, and Geography

발행일: 2024년 11월 | 리서치사:

The Insight Partners | 페이지 정보: 영문 203 Pages | 배송안내 : 즉시배송

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 항생제 및 항진균제 시장은 2023년 612억 달러에서 2031년 915억 4,000만 달러에 달할 것으로 예상되며, 2023-2031년 연평균 5.2%의 CAGR을 기록할 것으로 예측됩니다. 항생제 및 항진균제 시장의 성장은 노인 인구의 증가, 치과 질환의 부담 증가, 미용 치과에 대한 수요 급증에 기인합니다.

항생제와 항진균제는 다양한 종류의 병원균을 표적으로 하는 항균제입니다. 항생제는 세균을 죽이는 살균성 항생제(페니실린계, 세팔로스포린계)와 세균의 증식을 억제하는 정균성 항생제(테트라사이클린계, 마크로리드계)로 나뉩니다. 항생제는 세균 감염 치료에 널리 사용되고 있지만, 항생제 내성 균주의 증가로 인해 그 효과에 대한 의문이 제기되고 있습니다. 항진균제는 곰팡이 감염에 특화된 약물입니다. 항진균제는 진균의 세포 구조와 대사의 다양한 측면을 표적으로 삼아 효과를 발휘합니다. 일반적인 항진균제에는 아졸계(플루코나졸), 폴리엔계(암포테리신 B), 에키노칸딘계(카스포펀진) 등이 있습니다. 항진균제는 칸디다증, 아스페르길루스증 등 곰팡이로 인한 질병을 치료하는 데 필수적입니다.

북미 항생제 및 항진균제 시장은 미국, 캐나다, 멕시코로 구분됩니다. 이 시장은 주로 세균 및 진균 감염증의 유병률 증가, 신흥 시장의 의료 인프라의 존재, 이러한 감염증을 치료할 수 있는 다양한 항생제 및 항진균제의 가용성 등이 주요 요인으로 작용하고 있습니다. 또한, 제품 출시, 승인 및 기타 주요 기업의 전략적 이니셔티브의 증가는 예측 기간 동안 시장 성장 기회를 창출할 것으로 예상됩니다.

북미에서 미국은 항생제 및 항진균제의 가장 큰 시장입니다. 미국 항생제 및 항진균제 시장의 성장을 주도하는 것은 곰팡이 및 세균 감염의 유병률 증가와 효과적인 치료 옵션에 대한 수요 증가입니다. 폐렴은 미국에서 가장 흔한 호흡기 감염 질환으로, Verywell Health Journal 2024 보고서에 따르면 매년 미국에서 약 1,500만 명의 성인이 폐렴 진단을 받고 그 중 약 100만 명이 입원하고 5만 명이 폐렴 및 관련 합병증으로 사망하는 것으로 나타났습니다. 아목시실린과 아지트로마이신은 미국에서 세균 감염 치료를 위해 외래에서 가장 많이 처방되는 항생제입니다. 또한 제약 연구와 기술 발전으로 새로운 항생제 및 항진균제 개발이 가속화되고 있으며, 항생제 내성에 대한 우려와 혁신적인 치료법에 대한 필요성이 증가하고 있습니다. 또한 항균제 스튜어드십 프로그램의 중요성에 대한 인식이 높아지면서 항생제 처방에 대한 보다 신중한 접근이 이루어지고 있으며, 표적치료제와 병용요법으로의 전환이 가속화되고 있습니다. 이는 특히 병원 환경에서 두드러지게 나타나는데, 병원내 감염의 증가로 인해 강력한 항균제 사용이 요구되고 있습니다.

주요 기업들은 제품 출시, 제품 승인, 제휴 등의 전략적 이니셔티브를 취하고 있으며, 이는 예측 기간 동안 시장 성장을 뒷받침할 것으로 예상됩니다. 예를 들어, 2024년 4월 미국 식품의약국(FDA)은 Zevtera(주사용 세프토비프롤레 메드칼릴 나트륨)를 우측 감염성 심내막염을 포함한 황색포도상구균 혈류감염증(SAB)을 앓고 있는 성인과 급성 세균성 피부 및 피부 구조적 감염(ABSSSI)을 앓고 있는 성인을 위한 치료제로 승인했습니다. 또한, 미국 식품의약국(US Food and Drug Administration)은 2023년 3월 칸디다혈증 및 침습성 칸디다증 치료제로 REZZAYO(주사제 레자펑진)를 승인했습니다.

제품 개발 및 치료 전달 방식에 있어서의 기술 발전

제약 업계는 새로운 항생제 개발에 딥러닝, 인공지능(AI), 머신러닝과 같은 지능형 기술을 도입하는 데 중점을 두고 있습니다. 연구자들은 새로운 활성 화합물을 식별하기 위한 도구와 플랫폼을 구축하기 위해 노력하고 있습니다. 새로운 항생제 발견에 새로운 기술의 역량을 활용하면 항생제 및 항진균제 개발 및 승인 과정의 전반적인 흐름을 바꿀 수 있을 것으로 기대되고 있습니다.

그람 음성균에 대한 항생제 개발은 연구자들에게 큰 도전 과제이며, 많은 약물이 아직 개발 단계에 있습니다. 이 박테리아의 외피는 영양 특이적 단백질 채널(폴린)에 의해 투과성이 제한되어 막을 통한 비필수 분자(항생제 포함)의 이동이 제한됩니다. 연구진은 세포막 투과성을 둘러싼 어려움을 고려하여 폴린 분석을 기반으로 잠재적 약물 분자를 식별하는 데 도움이 되는 새로운 계산 항생제 스크리닝 플랫폼(CLASP)을 개발했습니다. CLASP는 조악화(CG) 해상도, 고급 샘플링 기술, 병렬 컴퓨팅 환경 등의 이점을 통해 CLASP의 성능을 극대화합니다. 이 플랫폼은 연구 대상의 잠재적 약물 분자에 대한 열역학적 및 동역학적으로 완전한 결과를 몇 시간 내에 제공합니다. 또한, 침투성이 높은 항생제를 발견하기 위한 구조-물성 상관관계를 제공하는 저분자 라이브러리를 이해하고 식별하는 데도 도움이 됩니다.

환자의 유전자 프로필과 대규모 집단에 공통적으로 나타나는 내성 패턴에 따라 항생제 치료를 조정하는 정밀의료에 대한 관심이 높아지고 있습니다. 이러한 혁명은 부작용을 최소화하고 내성균의 발생을 억제하는 동시에 약물의 기능을 향상시킬 수 있을 것으로 보입니다. 파지 치료는 기존의 미생물 치료와 박테리오파지를 결합하여 항생제 내성 병원균을 표적으로 삼고 파괴할 수 있는 또 다른 새로운 접근법으로 등장했으며, 최근 CRISPR과 같은 유전자 편집 기술의 유망한 발전은 파지 치료의 가능성을 더욱 높여줄 수 있습니다. 파지 치료의 가능성을 더욱 높일 수 있는 힘을 가지고 있습니다. 이와 같이 약물 개발 및 치료 전달 방식에 대한 기술 발전은 향후 몇 년 동안 항생제 및 항진균제 시장의 성장에 새로운 성장 동력을 제공할 것으로 예상됩니다.

항생제 및 항진균제 시장 : 경쟁 상황 및 주요 개발 동향

Pfizer Inc, Novartis AG, Sanofi SA, F. Hoffmann-La Roche Ltd, Merck & Co Inc, GSK Plc, Johnson & Johnson, Cipla Ltd, Bayer AG, AbbVie Inc, Astellas Pharma Inc 등이 항생제 및 항진균제 시장의 주요 기업입니다.

미국 식품의약국(FDA), 국립보건원(National Institute of Health), 국제연합아동기금(UNICEF), 세계보건기구(WHO), 미국 식품의약국(FDA), 미국 국립보건원(NIH), 국제연합아동기금(UNICEF) Organization(WHO), National Notifiable Diseases Surveillance System 등은 항생제 및 항진균제 시장 보고서를 작성할 때 참조한 1차 및 2차 정보 중 하나입니다.

항생제 및 항진균제 시장 - 주요 시장 역학
시장 성장 촉진요인
- 감염증 이환율 증가
- 진균 감염증에 대한 인식 확산
시장 성장 억제요인
- 항균제 내성, 경제적 장벽, 광범위한 규제 프로세스
시장 기회
- 지속적인 자금 조달과 연구개발 이니셔티브
향후 동향
- 제품 개발과 치료 제공 접근법의 기술 진보
성장 촉진요인과 저해요인의 영향

제6장 항생제 및 항진균제 시장 : 세계 시장 분석

항생제 및 항진균제 시장 매출, 2021-2031년
항생제 및 항진균제 시장 예측 분석

제7장 항생제 및 항진균제 시장 분석 : 약물 종류별

페니실린
세팔로스포린
카바페넴계 항생제
매크로라이드
아미노글리코사이드
퀴놀론계 항균제
설폰아미드계
테트라사이클린계 항생제
아졸계
기타

제8장 항생제 및 항진균제 시장 분석 : 적응증별

피부 감염증
호흡기 감염증
요로감염(UTI)
패혈증
귀 감염
소화기 감염증
기타

제9장 항생제 및 항진균제 시장 분석 : 투여 경로별

경구제
국소 투여
기타

제10장 항생제 및 항진균제 시장 분석 : 유통 채널별

병원 약국
소매 약국
온라인 약국

제11장 항생제 및 항진균제 시장 : 지역별 분석

북미
- 미국
- 캐나다
- 멕시코
유럽
- 독일
- 프랑스
- 스페인
- 이탈리아
- 영국
- 기타 유럽
아시아태평양
- 중국
- 일본
- 인도
- 호주
- 한국
- 기타 아시아태평양
중동 및 아프리카
- 사우디아라비아
- 남아프리카공화국
- 아랍에미리트
- 기타 중동 및 아프리카
중남미
- 브라질
- 아르헨티나
- 기타 중남미

제12장 항생제 및 항진균제 시장 - 업계 상황

항생제 및 항진균제 시장의 성장 전략
유기적 성장 전략
무기적 성장 전략

제13장 기업 개요

Pfizer Inc
Novartis AG
Sanofi SA
F. Hoffmann-La Roche Ltd
Merck & Co Inc
GSK Plc
Johnson & Johnson
Cipla Ltd
Bayer AG
AbbVie Inc
Astellas Pharma Inc

제14장 부록

ksm 24.11.26

The global antibiotics and antimycotics market is anticipated to grow from US$ 61.20 billion in 2023 and is projected to reach US$ 91.54 billion by 2031; it is expected to register a CAGR of 5.2% during 2023-2031. The antibiotics and antimycotics market growth is attributed to the increasing geriatric population, the growing burden of dental diseases, and the surging demand for cosmetic dentistry.

Antibiotics and antimycotics are antimicrobial agents targeting different types of pathogens. Antibiotics are further classified into bactericidal antibiotics, which kill bacteria (penicillins and cephalosporins), and bacteriostatic antibiotics, which inhibit bacterial growth (tetracyclines and macrolides). Antibiotics are widely used to treat bacterial infections, but their effectiveness is challenged by the rise of antibiotic-resistant strains. Antimycotics are specifically designed to combat fungal infections. They work by targeting various aspects of fungal cell structure or metabolism. Common classes of antimycotics include azoles (fluconazole), polyenes (amphotericin B), and echinocandins (caspofungin). Antimycotics are essential in treating conditions caused by fungi, such as candidiasis and aspergillosis.

The North America antibiotics and antimycotics market is segmented into the US, Canada, and Mexico. The market is mainly driven by the rising prevalence of bacterial and fungal infections, the presence of developed healthcare infrastructure, and the availability of a wide range of antibiotics and antimycotics for the treatment of such infections. Additionally, the rise in product launches, approvals, and other strategic initiatives by major players is expected to create opportunities for the market growth during the forecast period.

In North America, the US is the largest market for antibiotics and antimycotics. The US antibiotics and antimycotics market growth is driven by the increasing prevalence of fungal and bacterial infections and the growing need for effective treatment options. Pneumonia is the most common respiratory infection in the US. According to Verywell Health Journal 2024 report, every year, ~1.5 million adults in the US are diagnosed with pneumonia; of which around 1 million are admitted to hospitals while 50,000 people die due to pneumonia or related complications. Amoxicillin and azithromycin are the most commonly used antibiotics prescribed in the US in outpatient settings for the treatment of bacterial infections. In addition, with ongoing advancements in pharmaceutical research and technology, the development of new antibiotics and antifungal agents has gained momentum, responding to the growing concerns about antibiotic resistance and the need for innovative therapies. Moreover, the growing awareness about the importance of antimicrobial stewardship programs has led to a more cautious approach to antibiotic prescription, prompting a shift toward targeted therapies and combination treatments. This is particularly evident in hospital settings, where the growing incidence of hospital-acquired infections necessitates the use of potent antimicrobials.

Key players are taking strategic initiatives such as product launches, product approvals, and collaborations, which are expected to support the market growth during the forecast period. For instance, in April 2024, the US Food and Drug Administration (FDA) approved Zevtera (ceftobiprole medocaril sodium for injection) for the treatment of adults suffering from Staphylococcus aureus bloodstream infections (SAB), including those with right-sided infective endocarditis and adults suffering from acute bacterial skin and skin structure infections (ABSSSI). Additionally, in March 2023, The US FDA approved REZZAYO (rezafungin for injection) for the treatment of candidemia and invasive candidiasis.

Technological Advancements in Product Development and Treatment Delivery Approaches

The pharmaceutical industry emphasizes incorporating intelligent technologies such as deep learning, artificial intelligence (AI), and machine learning in the development of new antibiotics. Researchers are working to establish tools and platforms for identifying new active compounds. Harnessing the capabilities of novel technologies in new antibiotic discoveries is expected to change the overall course of antibiotic and antimycotic development and approval processes.

Developing antibiotics for Gram-negative bacteria poses a significant challenge to researchers, and many drugs are still in the development phases. Limited permeability across the envelope of these bacteria due to nutrient-specific protein channels (porins) restricts the movement of non-essential molecules (including antibiotics) across membranes. Considering the difficulties around cell membrane permeability, researchers have developed a new Computational Antibiotic Screening Platform (CLASP) that helps identify potential drug molecules based on the analysis of porins. Advantages such as coarse grain (CG) resolution, advanced sampling techniques, and a parallel computing environment maximize the performance of CLASPs. The platform provides complete thermodynamic and kinetic results for a potential drug molecule under study in a few hours. It also helps understand or identify small molecule libraries that yield structure-property relationships to discover antibiotics with high permeability.

There is a rising inclination toward precision medicine approaches that involve adjusting antibiotic treatments based on patients' genetic profiles and resistance patterns that are common among large populations. Such a revolution would improve drugs' functionality while ensuring minimal adverse effects and curbing the development of resistance. Phage therapy has emerged as another novel approach that involves a potential combination of traditional microbial treatments with bacteriophages to target and destroy antibiotic-resistant pathogens. Promising recent advancements in gene-editing technologies, such as CRISPR, has the ability to further enhance the prospects of phage therapy. Thus, technological advancements in drug development and treatment delivery approaches are expected to bring new growth trends in the antibiotics and antimycotics market growth in the coming years.

Antibiotics and Antimycotics Market: Competitive Landscape and Key Developments

Pfizer Inc, Novartis AG, Sanofi SA, F. Hoffmann-La Roche Ltd, Merck & Co Inc, GSK Plc, Johnson & Johnson, Cipla Ltd, Bayer AG, AbbVie Inc, and Astellas Pharma Inc. are among the key companies operating in the antibiotics and antimycotics market.

The US Food and Drug Administration, National Institute of Health, United Nations International Children's Emergency Fund (UNICEF), World Health Organization (WHO), National Notifiable Diseases Surveillance System are among the primary and secondary sources referred to while preparing the antibiotics and antimycotics market report.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:

4. Antibiotics and Antimycotics Market Landscape

4.1 Overview
4.2 PEST Analysis

5. Antibiotics and Antimycotics Market - Key Market Dynamics

5.1 Antibiotics and Antimycotics Market - Key Market Dynamics
5.2 Market Drivers:
- 5.2.1 Increasing Prevalence of Infectious Diseases
- 5.2.2 Growing Awareness About Fungal Infections
5.3 Market Restraints
- 5.3.1 Antimicrobial Resistance, Financial Barriers, and Extensive Regulatory Processes
5.4 Market Opportunities
- 5.4.1 Ongoing Funding and Research & Development Initiatives
5.5 Future Trends
- 5.5.1 Technological Advancements in Product Development and Treatment Delivery Approaches
5.6 Impact of Drivers and Restraints:

6. Antibiotics and Antimycotics Market - Global Market Analysis

6.1 Antibiotics and Antimycotics Market Revenue (US$ Million), 2021-2031
6.2 Antibiotics and Antimycotics Market Forecast Analysis

7. Antibiotics and Antimycotics Market Analysis - by Drug Class

7.1 Penicillin
- 7.1.1 Overview
- 7.1.2 Penicillin: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
7.2 Cephalosporines
- 7.2.1 Overview
- 7.2.2 Cephalosporines: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
7.3 Carbapenems
- 7.3.1 Overview
- 7.3.2 Carbapenems: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
7.4 Macrolides
- 7.4.1 Overview
- 7.4.2 Macrolides: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
7.5 Aminoglycosides
- 7.5.1 Overview
- 7.5.2 Aminoglycosides: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
7.6 Quinolones
- 7.6.1 Overview
- 7.6.2 Quinolones: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
7.7 Sulfonamides
- 7.7.1 Overview
- 7.7.2 Sulfonamides: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
7.8 Tetracyclines
- 7.8.1 Overview
- 7.8.2 Tetracyclines: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
7.9 Azoles
- 7.9.1 Overview
- 7.9.2 Azoles: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
7.10 Others
- 7.10.1 Overview
- 7.10.2 Others: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)

8. Antibiotics and Antimycotics Market Analysis - by Indication

8.1 Skin Infections
- 8.1.1 Overview
- 8.1.2 Skin Infections: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
8.2 Respiratory Infections
- 8.2.1 Overview
- 8.2.2 Respiratory Infections: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
8.3 Urinary Tract Infections (UTI)
- 8.3.1 Overview
- 8.3.2 Urinary Tract Infections (UTI): Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
8.4 Septicemia
- 8.4.1 Overview
- 8.4.2 Septicemia: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
8.5 Ear Infections
- 8.5.1 Overview
- 8.5.2 Ear Infections: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
8.6 Gastrointestinal Infections
- 8.6.1 Overview
- 8.6.2 Gastrointestinal Infections: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
8.7 Others
- 8.7.1 Overview
- 8.7.2 Others: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)

9. Antibiotics and Antimycotics Market Analysis - by Route Of Administration

9.1 Oral
- 9.1.1 Overview
- 9.1.2 Oral: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
9.2 Topical
- 9.2.1 Overview
- 9.2.2 Topical: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
9.3 Others
- 9.3.1 Overview
- 9.3.2 Others: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)

10. Antibiotics and Antimycotics Market Analysis - by Distribution Channel

10.1 Hospital Pharmacies
- 10.1.1 Overview
- 10.1.2 Hospital Pharmacies: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
10.2 Retail Pharmacies
- 10.2.1 Overview
- 10.2.2 Retail Pharmacies: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
10.3 Online Pharmacies
- 10.3.1 Overview
- 10.3.2 Online Pharmacies: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)

11. Antibiotics and Antimycotics Market - Geographical Analysis

11.1 North America
- 11.1.1 North America Antibiotics and Antimycotics Market Overview
- 11.1.2 North America: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  - 11.1.2.1 North America: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Drug Class
  - 11.1.2.2 North America: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Indication
  - 11.1.2.3 North America: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Route Of Administration
  - 11.1.2.4 North America: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Distribution Channel
- 11.1.3 North America: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Country
  - 11.1.3.1 United States: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.1.3.1.1 United States: Antibiotics and Antimycotics Market Breakdown, by Drug Class
    - 11.1.3.1.2 United States: Antibiotics and Antimycotics Market Breakdown, by Indication
    - 11.1.3.1.3 United States: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
    - 11.1.3.1.4 United States: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
  - 11.1.3.2 Canada: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.1.3.2.1 Canada: Antibiotics and Antimycotics Market Breakdown, by Drug Class
    - 11.1.3.2.2 Canada: Antibiotics and Antimycotics Market Breakdown, by Indication
    - 11.1.3.2.3 Canada: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
    - 11.1.3.2.4 Canada: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
  - 11.1.3.3 Mexico: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.1.3.3.1 Mexico: Antibiotics and Antimycotics Market Breakdown, by Drug Class
    - 11.1.3.3.2 Mexico: Antibiotics and Antimycotics Market Breakdown, by Indication
    - 11.1.3.3.3 Mexico: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
    - 11.1.3.3.4 Mexico: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
11.2 Europe
- 11.2.1 Europe Antibiotics and Antimycotics Market Overview
- 11.2.2 Europe: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  - 11.2.2.1 Europe: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Drug Class
  - 11.2.2.2 Europe: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Indication
  - 11.2.2.3 Europe: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Route Of Administration
  - 11.2.2.4 Europe: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Distribution Channel
- 11.2.3 Europe: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Country
  - 11.2.3.1 Germany: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.2.3.1.1 Germany: Antibiotics and Antimycotics Market Breakdown, by Drug Class
    - 11.2.3.1.2 Germany: Antibiotics and Antimycotics Market Breakdown, by Indication
    - 11.2.3.1.3 Germany: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
    - 11.2.3.1.4 Germany: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
  - 11.2.3.2 France: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.2.3.2.1 France: Antibiotics and Antimycotics Market Breakdown, by Drug Class
    - 11.2.3.2.2 France: Antibiotics and Antimycotics Market Breakdown, by Indication
    - 11.2.3.2.3 France: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
    - 11.2.3.2.4 France: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
  - 11.2.3.3 Spain: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.2.3.3.1 Spain: Antibiotics and Antimycotics Market Breakdown, by Drug Class
    - 11.2.3.3.2 Spain: Antibiotics and Antimycotics Market Breakdown, by Indication
    - 11.2.3.3.3 Spain: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
    - 11.2.3.3.4 Spain: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
  - 11.2.3.4 Italy: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.2.3.4.1 Italy: Antibiotics and Antimycotics Market Breakdown, by Drug Class
    - 11.2.3.4.2 Italy: Antibiotics and Antimycotics Market Breakdown, by Indication
    - 11.2.3.4.3 Italy: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
    - 11.2.3.4.4 Italy: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
  - 11.2.3.5 United Kingdom: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.2.3.5.1 United Kingdom: Antibiotics and Antimycotics Market Breakdown, by Drug Class
    - 11.2.3.5.2 United Kingdom: Antibiotics and Antimycotics Market Breakdown, by Indication
    - 11.2.3.5.3 United Kingdom: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
    - 11.2.3.5.4 United Kingdom: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
  - 11.2.3.6 Rest of Europe: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.2.3.6.1 Rest of Europe: Antibiotics and Antimycotics Market Breakdown, by Drug Class
    - 11.2.3.6.2 Rest of Europe: Antibiotics and Antimycotics Market Breakdown, by Indication
    - 11.2.3.6.3 Rest of Europe: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
    - 11.2.3.6.4 Rest of Europe: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
11.3 Asia Pacific
- 11.3.1 Asia Pacific Antibiotics and Antimycotics Market Overview
- 11.3.2 Asia Pacific: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  - 11.3.2.1 Asia Pacific: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Drug Class
  - 11.3.2.2 Asia Pacific: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Indication
  - 11.3.2.3 Asia Pacific: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Route Of Administration
  - 11.3.2.4 Asia Pacific: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Distribution Channel
- 11.3.3 Asia Pacific: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Country
  - 11.3.3.1 China: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.3.3.1.1 China: Antibiotics and Antimycotics Market Breakdown, by Drug Class
    - 11.3.3.1.2 China: Antibiotics and Antimycotics Market Breakdown, by Indication
    - 11.3.3.1.3 China: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
    - 11.3.3.1.4 China: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
  - 11.3.3.2 Japan: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.3.3.2.1 Japan: Antibiotics and Antimycotics Market Breakdown, by Drug Class
    - 11.3.3.2.2 Japan: Antibiotics and Antimycotics Market Breakdown, by Indication
    - 11.3.3.2.3 Japan: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
    - 11.3.3.2.4 Japan: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
  - 11.3.3.3 India: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.3.3.3.1 India: Antibiotics and Antimycotics Market Breakdown, by Drug Class
    - 11.3.3.3.2 India: Antibiotics and Antimycotics Market Breakdown, by Indication
    - 11.3.3.3.3 India: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
    - 11.3.3.3.4 India: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
  - 11.3.3.4 Australia: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.3.3.4.1 Australia: Antibiotics and Antimycotics Market Breakdown, by Drug Class
    - 11.3.3.4.2 Australia: Antibiotics and Antimycotics Market Breakdown, by Indication
    - 11.3.3.4.3 Australia: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
    - 11.3.3.4.4 Australia: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
  - 11.3.3.5 South Korea: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.3.3.5.1 South Korea: Antibiotics and Antimycotics Market Breakdown, by Drug Class
    - 11.3.3.5.2 South Korea: Antibiotics and Antimycotics Market Breakdown, by Indication
    - 11.3.3.5.3 South Korea: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
    - 11.3.3.5.4 South Korea: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
  - 11.3.3.6 Rest of APAC: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.3.3.6.1 Rest of APAC: Antibiotics and Antimycotics Market Breakdown, by Drug Class
    - 11.3.3.6.2 Rest of APAC: Antibiotics and Antimycotics Market Breakdown, by Indication
    - 11.3.3.6.3 Rest of APAC: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
    - 11.3.3.6.4 Rest of APAC: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
11.4 Middle East and Africa
- 11.4.1 Middle East and Africa Antibiotics and Antimycotics Market Overview
- 11.4.2 Middle East and Africa: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  - 11.4.2.1 Middle East and Africa: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Drug Class
  - 11.4.2.2 Middle East and Africa: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Indication
  - 11.4.2.3 Middle East and Africa: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Route Of Administration
  - 11.4.2.4 Middle East and Africa: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Distribution Channel
- 11.4.3 Middle East and Africa: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Country
  - 11.4.3.1 Saudi Arabia: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.4.3.1.1 Saudi Arabia: Antibiotics and Antimycotics Market Breakdown, by Drug Class
    - 11.4.3.1.2 Saudi Arabia: Antibiotics and Antimycotics Market Breakdown, by Indication
    - 11.4.3.1.3 Saudi Arabia: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
    - 11.4.3.1.4 Saudi Arabia: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
  - 11.4.3.2 South Africa: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.4.3.2.1 South Africa: Antibiotics and Antimycotics Market Breakdown, by Drug Class
    - 11.4.3.2.2 South Africa: Antibiotics and Antimycotics Market Breakdown, by Indication
    - 11.4.3.2.3 South Africa: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
    - 11.4.3.2.4 South Africa: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
  - 11.4.3.3 United Arab Emirates: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.4.3.3.1 United Arab Emirates: Antibiotics and Antimycotics Market Breakdown, by Drug Class
    - 11.4.3.3.2 United Arab Emirates: Antibiotics and Antimycotics Market Breakdown, by Indication
    - 11.4.3.3.3 United Arab Emirates: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
    - 11.4.3.3.4 United Arab Emirates: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
  - 11.4.3.4 Rest of Middle East and Africa: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.4.3.4.1 Rest of Middle East and Africa: Antibiotics and Antimycotics Market Breakdown, by Drug Class
    - 11.4.3.4.2 Rest of Middle East and Africa: Antibiotics and Antimycotics Market Breakdown, by Indication
    - 11.4.3.4.3 Rest of Middle East and Africa: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
    - 11.4.3.4.4 Rest of Middle East and Africa: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
11.5 South and Central America
- 11.5.1 South and Central America Antibiotics and Antimycotics Market Overview
- 11.5.2 South and Central America: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
  - 11.5.2.1 South and Central America: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Drug Class
  - 11.5.2.2 South and Central America: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Indication
  - 11.5.2.3 South and Central America: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Route Of Administration
  - 11.5.2.4 South and Central America: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Distribution Channel
- 11.5.3 South and Central America: Antibiotics and Antimycotics Market - Revenue and Forecast Analysis - by Country
  - 11.5.3.1 Brazil: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.5.3.1.1 Brazil: Antibiotics and Antimycotics Market Breakdown, by Drug Class
    - 11.5.3.1.2 Brazil: Antibiotics and Antimycotics Market Breakdown, by Indication
    - 11.5.3.1.3 Brazil: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
    - 11.5.3.1.4 Brazil: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
  - 11.5.3.2 Argentina: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.5.3.2.1 Argentina: Antibiotics and Antimycotics Market Breakdown, by Drug Class
    - 11.5.3.2.2 Argentina: Antibiotics and Antimycotics Market Breakdown, by Indication
    - 11.5.3.2.3 Argentina: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
    - 11.5.3.2.4 Argentina: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel
  - 11.5.3.3 Rest of South and Central America: Antibiotics and Antimycotics Market - Revenue and Forecast to 2031 (US$ Million)
    - 11.5.3.3.1 Rest of South and Central America: Antibiotics and Antimycotics Market Breakdown, by Drug Class
    - 11.5.3.3.2 Rest of South and Central America: Antibiotics and Antimycotics Market Breakdown, by Indication
    - 11.5.3.3.3 Rest of South and Central America: Antibiotics and Antimycotics Market Breakdown, by Route Of Administration
    - 11.5.3.3.4 Rest of South and Central America: Antibiotics and Antimycotics Market Breakdown, by Distribution Channel

12. Antibiotics and Antimycotics Market - Industry Landscape

12.1 Overview
12.2 Growth Strategies in Antibiotics and Antimycotics Market
12.3 Organic Growth Strategies
- 12.3.1 Overview
12.4 Inorganic Growth Strategies
- 12.4.1 Overview

13. Company Profiles

13.1 Pfizer Inc
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Novartis AG
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Sanofi SA
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 F. Hoffmann-La Roche Ltd
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Merck & Co Inc
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 GSK Plc
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Johnson & Johnson
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Cipla Ltd
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 Bayer AG
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 AbbVie Inc
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments
13.11 Astellas Pharma Inc
- 13.11.1 Key Facts
- 13.11.2 Business Description
- 13.11.3 Products and Services
- 13.11.4 Financial Overview
- 13.11.5 SWOT Analysis
- 13.11.6 Key Developments

14. Appendix

14.1 About The Insight Partners
14.2 Glossary of Terms